The role of microRNAs in breast cancer stem cells

doi:10.3760/cma.j.issn.1673-422X.2014.12.002

Abstract

Abstract: The role of microRNAs in breast cancer stem cellsMao Changfei, Wu Jianzhong, Tang Jinhai. Corresponding author:【Abstract】Cancer stem cells are a kind of cancer cell group with the ability of selfrenewal and various diferentiation potentials. Recent studies have implicated that they play a significant role in tumor formation, metastasis, resistance to anticancer therapies and cancer recurrence. Many studies show that microRNAs are involved in the maintenance, growth and behavior of breast cancer stem cells(BCSCs), paving a new way for diagnosis, prognosis and therapy of breast cancer.

Key words: MicroRNAs, Neoplastic stem cells, Breast neoplasms

MAO Chang-Fei, WU Jian-Zhong, TANG Jin-Hai. The role of microRNAs in breast cancer stem cells[J]. Journal of International Oncology, 2014, 41(12): 884-887.

References

［1］ Wicha MS, Liu S, Dontu G. Cancer stem cells: an old ideaa paradigm shift［J］. Cancer Res, 2006, 66(4): 18831890. ［2］ NanaSinkam SP, Croce CM. Clinical applications for micrornas in cancer［J］. Clin Pharmacol Ther, 2013, 93(1): 98104. ［3］ Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microrna expression confined to specific epithelial cell subpopulations in breast cancer［J］. Cancer Res, 2007, 67(24): 1161211620. ［4］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 11091123. ［5］ Johnson CD, EsquelaKerscher A, Stefani G, et al. The let7 microrna represses cell proliferation pathways in human cells［J］. Cancer Res, 2007, 67(16): 77137722. ［6］ Wang Y, Hu X, Greshock J, et al. Genomic DNA copynumber alterations of the let7 family in human cancers［J］. PLoS One, 2012, 7(9): e44399. ［7］ Ambros V. Micrornas: Tiny regulators with great potential［J］. Cell, 2001, 107(7): 823826. ［8］ Yu F, Deng H, Yao H, et al. Mir30 reduction maintains selfrenewal and inhibits apoptosis in breast tumorinitiating cells［J］. Oncogene, 2010, 29(29): 41944204. ［9］ Shimono Y, Zabala M, Cho RW, et al. Downregulation of mirna200c links breast cancer stem cells with normal stem cells［J］. Cell, 2009, 138(3): 592603. ［10］ Iliopoulos D, LindahlAllen M, Polytarchou C, et al. Loss of mir200 inhibition of suz12 leads to polycombmediated repression required for the formation and maintenance of cancer stem cells［J］. Mol cell, 2010, 39(5): 761772. ［11］ Okuda H, Xing F, Pandey PR, et al. miR7 suppresses brain metastasis of breast cancer stemlike cells by modulating klf4［J］. Cancer Res, 2013, 73(4): 14341444. ［12］ Zhu Y, Yu F, Jiao Y, et al. Reduced miR128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi1 and ABCC5［J］. Clin Cancer Res, 2011, 17(22): 71057115. ［13］ Qian P, Banerjee A, Wu ZS, et al. Loss of snail regulated mir1282 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells［J］. Cancer Res, 2012, 72(22): 60366050. ［14］ Yu F, Jiao Y, Zhu Y, et al. Microrna 34c gene downregulation via DNA methylation promotes selfrenewal and epithelialmesenchymal transition in breast tumorinitiating cells［J］. J Biol Chem, 2012, 287(1): 465473. ［15］ Zhang X, Wan G, Mlotshwa S, et al. Oncogenic wip1 phosphatase is inhibited by mir16 in the DNA damage signaling pathway［J］. Cancer Res, 2010, 70(18): 71767186. ［16］ HwangVerslues WW, Chang PH, Wei PC, et al. Mir495 is upregulated by e12/e47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of ecadherin and redd1［J］. Oncogene, 2011, 30(21): 24632474. ［17］ Zhang Y, Eades G, Yao Y, et al. Estrogen receptor alpha signaling regulates breast tumorinitiating cells by downregulating mir140 which targets the transcription factor SOX2［J］. J Biol Chem, 2012, 287(49): 4151441522. ［18］ Li Q, Yao Y, Eades G, et al. Downregulation of mir140 promotes cancer stem cell formation in basallike early stage breast cancer［J］. Oncogene, 2014, 33(20): 25892600.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.